About this trial
A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of CACNA1A. The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Written informed consent signed by the patient and/or their legal representative / parent/ impartial witness.
Male or female aged ≥4 years with a genetically-confirmed diagnosis of a CACNA1A Disorder (including patients with loss-of-function and fain-of-function mutations, e.g. Episodic Ataxia Type 2 (EA2), Familial Hemiplegic Migraine Type 1, Spinocerebellar Ataxia type C (SCA6), Developmental and Epileptic encephalopathy 42 (DEE42), Congenital ataxia or cerebellar hypoplasia due to a CACNA1A mutation) at the time of signing informed consent.
intrauterine device (IUD);
surgical sterilization of the partner (vasectomy for 6 months minimum);
Disqualifiers
Acetyl-Leucine (DL-, L-, D-) or derivatives.
Excipients the IB1001 sachet (namely isomalt, hypromellose, and strawberry flavor).
Excipients the placebo sachet (namely isomalt, hypromellose, strawberry flavor, citric acid, microcrystalline cellulose, lactose, denatonium benzoate).
Simultaneous participation in another clinical study or participation in any clinical study involving administration of an investigational medicinal product (IMP; 'study drug') for at least 42 days prior to Visit 1. At the discretion of the Investigator, Medical Monitor, and Sponsor, the washout period for specific IMPs may be longer based on the pharmacological activity and pharmacokinetics of the drug.
Trial design
Crossover
Treatments tested in this trial
N-Acetyl-L-Leucine
DrugN-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
Placebo
Other interventionMatching Placebo Sachet
Treatment groups
Trial outcomes
Primary outcomes
Scale for the Assessment and Rating of Ataxia
The Scale for Assessment and Rating of Ataxia has 8 items that are related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements, and heel-shin test. The range is 0-40 points, with a lower score representing neurological improvement and a higher score representing neurological worsening.
Secondary outcomes
Spinocerebellar Ataxia Functional Index (SCAFI)
Spinocerebellar Ataxia Functional Index (SCAFI) is composed of 8 Meter Walk Test, 9-Hole Peg Test of Dominant and Non-Dominant Hand (9HPT-D/9HPT-ND) (the 3 tests are timed assessments; each is done twice and values are averaged; the 8MWT and 9HPT-D and 9HPT-ND values are converted from times to rates, and the results expressed as a composite Z-score of each test relative to baseline) and the PATA rate (counted number how often a patient can repeat the syllables "PATA" within 10 seconds), a measure of speech performance. The scores of these 3 were transformed to Z-scores (=individual's average of both trials to perform the respective task - mean of study population at baseline) / SD of study population at baseline). A Z-score of 0 equates to the population mean at baseline. For all 3, higher Z-scores (above mean) mean better performance. The SCAFI total score was calculated as the arithmetic mean of the non-missing Z-scores for the 3. A higher total score means better performance.
Physician's / Caregiver's / Patient's Clinical Global Impressions (CGI)
The Clinical Global Impression of Improvement assessed by the investigator/caregiver/patient is evaluated on a 7 point Likert scale ranging from 1='very much improved' to 7='very much worse'
EuroQuol- 5 Dimension (EQ-5D) Quality of Life Scale
For posting, health-related quality of life based on the EQ-5D visual analogue scale (VAS) was presented as a secondary endpoint. EQ-5D VAS is a 0-100 scale where patients are asked to indicate their overall health, with a score of 0 indicating worst health and a score of 100 indicating best health.
Neuro Quality of Life - Upper Extremity Function (NeuroQOL-UEF)
The Neurology Quality of Life (NeuroQOL) Upper Extremity Function (UEF) scale is a self-report of health-related quality of life that measures the patient's ability to carry out various activities involving digital, manual, and reach-related functions, ranging from fine motor to self-care (activities of daily living). The NeuroQOL scale is approximately a 100-point scale, where 100 is the best functioning, and 0 is the worst.
Other outcomes
Scale for Ocular Motor Disorders in Ataxia
The Scale for Ocular Motor Dysfunction in Ataxia (SODA) is a 7-item clinical rating scale (ocular alignment, saccadic intrusions, jerk nystagmus, vestibulo-ocular reflex (VOR) cancellation, ocular pursuit, VOR, and saccades) evaluating the extend of ocular motor deficits in cerebellar disorders. The scale ranges from range -26, where 0 is the best status and 26 is the worst).
Epworth Sleepiness Scale
The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Patients (or the caregiver on the patient's behalf) are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in these activities at least occasionally, although not necessarily every day. The Epworth Sleepiness Scale score (the sum of 8 item scores, 0-3) can range from 0 to 24.
Frequency of Seizures
Patients and their caregivers will be asked to keep a diary of the frequency of seizures. Specifically, they will note the number of attacks of seizures, and days with seizures per week.
Frequency of Migraine Attacks
Patients and their caregivers will be asked to keep a diary of the frequency of migraines. Specifically, they will note the number of attacks of migraine, aura, and days with headache (including migraine) per week.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.